fAD1
MUNIi005-A
General
Cell Line |
|
| hPSCreg name | MUNIi005-A |
| Cite as: | MUNIi005-A (RRID:CVCL_A4PD) |
| Alternative name(s) |
fAD1
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
|
| Last update | 19th January 2021 |
| User feedback | |
Provider |
|
| Generator |
Masaryk University (MUNI)
Contact:
Masaryk University (MUNI) |
| Owner | Masaryk University (MUNI) |
| Distributors | |
| Derivation country | Czech Republic |
External Databases |
|
| BioSamples | SAMEA7873285 |
| Cellosaurus | CVCL_A4PD |
| Wikidata | Q105510220 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 55-59 |
| Ethnicity | Canadian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA7873286 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please provide the contact information | https://www.coriell.org/1/About-Us/Contact-Us |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | Yes |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | No |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | No |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | No |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does consent permit access to medical records of the donor? | No |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Coriell institute is holder of all documents |
| Approval number | |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Masaryk University |
| Approval number | MUNI/G/1131/2017 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Epi5™ Episomal iPSC Reprogramming Kit (cat.:A15960; ThermoFisher) |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell line name | AG06840 |
| Source cell type | |
| Source cell origin |
Synonyms
|
| Age of donor (at collection) | 55-59 |
| Source cell line vendor | Coriell Institute for Medical Research |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
Yes |
| Methods used |
PCR
|
| Notes on reprogramming vector detection | PCR detection of Epstein-Barr virus nuclear antigen 1 (EBNA1) gene and oriP element of Epi5™ Episomal iPSC Reprogramming Kit |
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | The main selection criteria were morphology, all tested clones have high expression of pluripotent markers |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex | ||||||
| Feeder cells |
No |
||||||
| Passage method |
Enzymatically
TrypLE
|
||||||
| O2 Concentration | 21 % | ||||||
| CO2 Concentration | 5 % | ||||||
| Medium |
mTeSR™ 1
Supplements
|
||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| TRA 1-81 |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| NANOG |
Yes |
|||||
| SOX2 |
Yes |
Morphology pictures
Differentiation Potency
In vitro spontaneous differentiation
Morphology
fAD1 D15
Protocol or reference
Cultivation protocols for PSCs.pdf
Embryoid bodies - polyhema 96W
In vitro spontaneous differentiation
| Marker | Expressed |
| BRACHYURY |
Yes |
Morphology
fAD1 D15
Protocol or reference
Cultivation protocols for PSCs.pdf
Embryoid bodies - polyhema 96W
In vitro spontaneous differentiation
Morphology
fAD1 D15
Protocol or reference
Cultivation protocols for PSCs.pdf
Embryoid bodies - polyhema 96W
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.